These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 14718041

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.
    Oyama N, Kim J, Jones LA, Mercer NM, Engelbach JA, Sharp TL, Welch MJ.
    Nucl Med Biol; 2002 Nov; 29(8):783-90. PubMed ID: 12453586
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [Abstract] [Full Text] [Related]

  • 27. Studies on the role of the sex-hormone-binding globulin (SHBG) in prostatic gland hypertrophy in men. II. In vitro research.
    Pachman A.
    Int Urol Nephrol; 1984 Feb; 16(3):211-7. PubMed ID: 6207132
    [Abstract] [Full Text] [Related]

  • 28. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997 Jul; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
    Meunier ME, Neuzillet Y, Raynaud JP, Radulescu C, Ghoneim T, Fiet J, Giton F, Rouanne M, Dreyfus JF, Lebret T, Botto H.
    Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Microautoradiographic studies on distribution of 5 alpha-dihydrotestosterone, cyproterone acetate and oestradiol-17 beta in human prostatic hyperplasia tissue transplanted to juvenile rats.
    Ruberg I, Senge T, Neumann F.
    Acta Endocrinol (Copenh); 1982 Sep; 101(1):144-53. PubMed ID: 6181639
    [Abstract] [Full Text] [Related]

  • 40. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
    Petrangeli E, Sciarra F, Di Silverio F, Toscano V, Lubrano C, Conti C, Concolino G.
    J Steroid Biochem; 1988 Sep; 30(1-6):395-9. PubMed ID: 2455099
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.